.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
US Department of Justice
Covington
Farmers Insurance
McKesson
Julphar
Novartis
Baxter
Argus Health
Healthtrust

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,933,086

« Back to Dashboard

Details for Patent: 8,933,086

Title:Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE), Fridman; Jordan S. (Newark, DE), Vaddi; Krishna (Kennett Square, PA)
Assignee: Incyte Corporation (Wilmington, DE)
Filing Date:Sep 20, 2013
Application Number:14/033,039
Claims:1. A method of treating pancreatic cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1, wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof.

3. A method according to claim 2, further comprising administering to said patient an additional therapeutic agent.

4. The method according to claim 3, wherein said additional therapeutic agent is a chemotherapeutic agent.

5. The method according to claim 4, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent simultaneously to the patient.

6. The method according to claim 4, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent sequentially to said patient.

7. The method according to claim 2, wherein about 5 to about 1000 mg of said compound or said salt is administered to said patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Fish and Richardson
Julphar
Boehringer Ingelheim
Cantor Fitzgerald
AstraZeneca
Citi
Baxter
Queensland Health
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot